This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A multi-centre, open-label, phase II study of the ...
Clinical trial

A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancer

Read time: 1 mins
Last updated:28th Nov 2006
The primary objective of this study is to evaluate the efficacy of CAP-232 as a monotherapy (each 28-day cycle consists of 21 days continuous IV infusion of CAP-232 at 0.5 mg/kg/day followed by a 7-day rest period) in patients with metastatic kidney cancer.
Category Value
Study start date 2006-11-28

View full details